SCHEMBL4730737

SCHEMBL4730737

CS(=O)(=O)OCC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29059948 0.97
SCHEMBL29111714 0.97
SCHEMBL4465842 0.79 USP2 (0.48)
SCHEMBL4465846 0.79 USP2 (0.48)
SCHEMBL6118063 0.79 USP2 (0.48)
SCHEMBL7569192 0.77
SCHEMBL6100147 0.77
SCHEMBL18954410 0.74
SCHEMBL11829047 0.74
SCHEMBL30711 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4659809-A2 STEROIDS AND PROTEIN-CONJUGATES THEREOF Regeneron Pharmaceuticals, Inc. (US) 2025-12-10 EP disclosed
EP-4651872-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS Septerna, Inc. (US) 2025-11-26 EP disclosed
EP-3538539-B1 STEROIDS AND PROTEIN-CONJUGATES THEREOF REGENERON PHARMA (US) 2025-08-27 EP disclosed
EP-4587030-A2 NOVEL GLUCOCORTICOID RECEPTOR AGONISTS AND IMMUNOCONJUGATES THEREOF Adcentrx Therapeutics Inc. (US) 2025-07-23 EP disclosed
WO-2024155601-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS SEPTERNA, INC. (US) 2024-07-25 WO disclosed
WO-2024059237-A2 NOVEL GLUCOCORTICOID RECEPTOR AGONISTS AND IMMUNOCONJUGATES THEREOF ADCENTRX THERAPEUTICS INC. (US) 2024-03-21 WO disclosed
US-11760775-B2 Steroids and protein-conjugates thereof REGENERON PHARMACEUTICALS, INC. 2023-09-19 US disclosed
CN-116749348-A Concrete mixing plant CO 2 System and method for sealing and utilizing 湖北工业大学 2023-09-15 CN disclosed
EP-4058464-A1 ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS Nuvation Bio Inc. (US) 2022-09-21 EP disclosed
CN-111393480-A Gold complex containing diphosphine o-carborane ligand and preparation method and application thereof 上海应用技术大学 2020-07-10 CN disclosed
US-9359376-B2 Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds SPHAERA PHARMA PTE. LTD (SG) 2016-06-07 US disclosed
EP-2238152-B1 PROCESSES FOR PREPARATION OF DUTASTERIDE GADOR SA (AR) 2015-02-18 EP disclosed
US-20140121367-A1 SUBSTITUTED METHYLFORMYL REAGENTS AND METHOD OF USING SAME TO MODIFY PHYSICOCHEMICAL AND/OR PHARMACOKINETIC PROPERTIES OF COMPOUNDS PIVOT HOLDING LLC 2014-05-01 US disclosed
WO-2008054155-A1 METHOD FOR THE PREPARATION OF OPTICALLY ACTIVE 2-SULFONYLOXY-1-PHENYLETHANOL DERIVATIVES KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-05-08 WO disclosed
CN-1934083-A 5-amino-4-hydroxy-7- (1H-indolylmethyl) -8-methylnonanamide derivatives as renin inhibitors for the treatment of hypertension SPEEDEL EXPERIMENTA AG (CH) 2007-03-21 CN disclosed
US-5158936-A Treating or prevention of tissue damage, inflammation, bone resporpption and muscular dystrophy SYNTEX (U.S.A.) INC. (US) 1992-10-27 US disclosed
US-5055451-A Prevent tissue damage SYNTEX INC. (US) 1991-10-08 US disclosed
EP-0021883-A2 N-acyl-amino acid derivatives and pharmaceutical compositions containing them, intermediates and starting compounds MERRELL TORAUDE ET COMPAGNIE (FR) 1981-01-07 EP disclosed